Francesco Gelsomino

机构：Azienda USL di Bologna, Istituti di Ricovero e Cura a Carattere Scientifico, University of Bologna · ORCID：0000-0002-9204-1728

发表论文 210 篇 · 总被引 3414 次 · h-index 30

代表论文

• Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50% (2025 · ESMO Open · 被引 5)
• Liquid Biopsy Monitoring in BRAF V600E–Mutated Patients With Non–Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020) (2026 · JCO Precision Oncology · 被引 1)
• Posterior Reversible Encephalopathy Syndrome with Angiogenesis Inhibitors for Solid Tumours: Clues from a Disproportionality Analysis of the FDA Adverse Event Reporting System and Pharmacodynamics (2026 · Targeted Oncology · 被引 1)
• Data from Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib (2026)
• Supplementary Tables1 from Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib (2026)
• Supplementary Figures1 from Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib (2026)